Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. [artículo]
Por: Coronado, C [Oncología Médica]
| Cortés-Funes Castro, Hernán [Oncología Médica] | López Martín, Ana [Oncología Médica] | Paz-Ares Rodríguez, Luis [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Editor: Cancer chemotherapy and pharmacology, 2013Descripción: 72(1):75-83.Recursos en línea: Solicitar documento Resumen: PURPOSE: Kahalalide F (KF) is a dehydroaminobutyric acid-containing peptide from marine origin with activity against several human malignant cell lines. This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommended dose for further phase II studies (RD) of weekly KF given as a prolonged (3- to 24-h) intravenous (i.v.) infusion.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC11239 (Navegar estantería) | Disponible |
Formato Vancouver:
Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C et al. Phase I study of weekly kahalalide
F as prolonged infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83.
PMID: 23645288
Contiene 18 referencias
PURPOSE: Kahalalide F (KF) is a dehydroaminobutyric acid-containing peptide from marine origin with activity against several human malignant cell lines. This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommended dose for further phase II studies (RD) of weekly KF given as a prolonged (3- to 24-h) intravenous (i.v.) infusion.
No hay comentarios para este ejemplar.